Promote a healthier life
for humankind through
advancements in science

Science-based

Benefit the patients with
high-quality medication as
we determined to innovate

Innovation-driven

Build a leading global
biopharmaceutical group
to serve more

Going Global

Fulfill social responsibilities
through accountable actions

Embrace Social
Responsibilities

Explore who we are

About us

Innovation is the core of our development strategy

Partnering

We are actively looking for synergistic partnerships

Walk into Hengrui

Est.

1970

New Molecular Entity drugs marketed in China

24

Other innovative drugs marketed in China

5

SH 600276

HK 1276

Est.

1970

Marketed Innovative Products in China

8

Partnered Innovative Product Launched

1

SH 600276

HK 1276

Pipeline

Our innovative pipeline covers the most of major therapeutic areas and continues to grow

Pipeline

Our innovative pipeline covers the most of major therapeutic areas and continues to grow

Investor

Enhance communication between our company and investors

Media

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Media

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

Media

Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial of HRS-7535 in Type 2 Diabetes and Phase 1 Trial of HRS-4729 Demonstrating Continued Execution Across Diversified GLP-1-Based Pipeline